Late last year, Novartis (NVS) began marketing a breakthrough gene therapy for treating youngsters with advanced leukemia and slapped a $475,000 price tag on the one-time treatment. The eye-popping number sparked debate, but the drug was quickly deemed cost effective by a nonprofit watchdog.

The controversy is far from over, though.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • It is perhaps a fine irony that the Baird analyst who is quoted above … “Sorry to be Debbie Downer, but Kymriah is never going to provide a positive ROI [return on investment], even at $475,000,” …. has the initials “BS.”
    He may have access to the numbers that are “proprietary” – and know the potential number of patients – but at the price, 2100 treatments (‘not including rebates’ etc) will cost just about $1 Billion USD.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy